The global High Purity Medical Grade Isosorbide market size was estimated at USD 239 million in 2023 and is projected to reach USD 373.96 million by 2032, exhibiting a CAGR of 5.10% during the forecast period.
North America High Purity Medical Grade Isosorbide market size was estimated at USD 67.84 million in 2023, at a CAGR of 4.37% during the forecast period of 2025 through 2032.
Ultra‑pure isosorbide for pharmaceutical applications, particularly in cardiovascular medications.
Cardiovascular drugs lead with 65% share, sustained release applications growing at 7.8%. High‑purity grades command 45% premium. Europe leads with 40% market share.
Global High Purity Medical Grade Isosorbide Market – View in Detailed Research Report
Market Insight
Pharmaceutical Grade Isosorbide is a high‑purity chemical used in the pharmaceutical field. Isosorbide is a diol extracted from plant‑derived materials (such as corn starch) and belongs to cyclic sugar alcohols. It has good biocompatibility and biodegradability, so it is widely used in the pharmaceutical field.
This report provides a deep insight into the global High Purity Medical Grade Isosorbide market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
🔟 1. Roquette
Headquarters: Paris, France
Key Offering: High‑purity Isosorbide for pharmaceutical applications
Roquette is a leading producer of high‑purity isosorbide, focusing on cardiovascular drug formulations and sustained‑release delivery systems. Their advanced purification processes enable a 99.9% purity level, meeting stringent pharmaceutical grade requirements.
Sustainability & Growth Initiatives:
- Investment in renewable feedstock sourcing from corn starch
- Carbon‑neutral production facilities across Europe
- Collaboration with pharma partners on green drug development
9️⃣ 2. SK Holdings
Headquarters: Seoul, South Korea
Key Offering: Ultra‑pure Isosorbide for cardiovascular drugs
SK Holdings supplies high‑purity isosorbide to leading Korean and global pharmaceutical companies, with a focus on sustained‑release cardiovascular therapies. Their manufacturing capabilities support a 99% purity standard, catering to premium drug formulations.
Sustainability & Growth Initiatives:
- Expansion of bio‑based feedstock processing plants
- Partnerships with green pharma initiatives
- Adoption of digital process monitoring for energy efficiency
8️⃣ 3. Ecogreen Oleochemicals
Headquarters: New Delhi, India
Key Offering: High‑purity Isosorbide for sustained‑release medicines
Ecogreen Oleochemicals focuses on producing 99.9% pure isosorbide, primarily for sustained‑release cardiovascular drugs. Their eco‑friendly production process aligns with global sustainability goals in pharma manufacturing.
Sustainability & Growth Initiatives:
- Zero‑waste production processes
- Renewable energy sourcing for plants
- Collaborations with Indian pharma for green drug development
7️⃣ 4. ADM
Headquarters: Chicago, Illinois, USA
Key Offering: High‑purity Isosorbide for pharmaceutical use
ADM, a global leader in agricultural and chemical production, supplies high‑purity isosorbide to pharmaceutical manufacturers. Their advanced purification technologies ensure consistent 99% purity suitable for cardiovascular drug applications.
Sustainability & Growth Initiatives:
- Investment in renewable feedstock from corn and soy
- Carbon capture and storage at production sites
- Strategic partnerships with pharma for sustainable drug supply chains
6️⃣ 5. Novaphene
Headquarters: St. Louis, Missouri, USA
Key Offering: Ultra‑pure Isosorbide for cardiovascular formulations
Novaphene specializes in high‑purity isosorbide used in cardiovascular drug manufacturing. Their production processes achieve 99.9% purity, enabling premium drug formulations with high bioavailability.
Sustainability & Growth Initiatives:
- Green chemistry initiatives to reduce solvent use
- Energy‑efficient production lines
- Collaborations with pharma for green drug development
5️⃣ 6. AECI
Headquarters: Copenhagen, Denmark
Key Offering: High‑purity Isosorbide for sustained‑release medicines
AECI produces high‑purity isosorbide for the pharmaceutical sector, focusing on cardiovascular drug delivery systems. Their advanced purification technologies support 99% purity levels.
Sustainability & Growth Initiatives:
- Renewable energy integration at plants
- Waste‑to‑energy projects
- Partnerships with pharma for eco‑friendly drug development
4️⃣ 7. DuPont
Headquarters: Wilmington, Delaware, USA
Key Offering: High‑purity Isosorbide for pharmaceutical use
DuPont supplies high‑purity isosorbide for cardiovascular drug manufacturing. Their production processes ensure 99.9% purity, meeting the highest pharmaceutical standards.
Sustainability & Growth Initiatives:
- Carbon‑neutral production goals
- Investment in renewable feedstocks
- Digital process optimization for energy savings
3️⃣ 8. BASF
Headquarters: Ludwigshafen, Germany
Key Offering: Ultra‑pure Isosorbide for cardiovascular drugs
BASF produces high‑purity isosorbide used in cardiovascular drug formulations. Their advanced purification technologies deliver 99% purity suitable for premium drug products.
Sustainability & Growth Initiatives:
- Renewable energy usage across production sites
- Zero‑waste manufacturing processes
- Collaboration with pharma for green drug development
2️⃣ 9. Evonik
Headquarters: Essen, Germany
Key Offering: High‑purity Isosorbide for pharmaceutical applications
Evonik supplies high‑purity isosorbide to pharmaceutical manufacturers, focusing on cardiovascular drug delivery systems. Their processes achieve 99.9% purity.
Sustainability & Growth Initiatives:
- Carbon capture and utilization projects
- Renewable feedstock sourcing
- Digital transformation for process efficiency
1️⃣ 10. ICI
Headquarters: London, United Kingdom
Key Offering: Ultra‑pure Isosorbide for cardiovascular drug manufacturing
ICI produces high‑purity isosorbide for cardiovascular drug formulations, ensuring 99.9% purity to meet stringent pharmaceutical standards.
Sustainability & Growth Initiatives:
- Green chemistry initiatives
- Renewable energy integration
- Partnerships with pharma for sustainable drug development
Download FREE Sample Report: Global High Purity Medical Grade Isosorbide Market – View in Detailed Research Report
Get Full Report: Global High Purity Medical Grade Isosorbide Market – View in Detailed Research Report
🌍 Outlook: The Future of High Purity Medical Grade Isosorbide
The high‑purity isosorbide market is evolving rapidly, driven by increasing demand for cardiovascular drugs and sustained‑release drug delivery systems. With a projected CAGR of 5.10%, the market will expand as pharmaceutical companies seek greener, more efficient manufacturing solutions.
📈 Key Trends Shaping the Market:
- Growth in cardiovascular drug formulations using high‑purity isosorbide
- Increased focus on sustainable feedstock and carbon‑neutral production
- Expansion of high‑purity isosorbide supply chains across Europe and North America
- Strategic partnerships between chemical producers and pharma companies
🔮 Future Trends
- Adoption of advanced purification technologies to achieve >99.9% purity
- Integration of digital twins for process optimization
- Emergence of bio‑based feedstock from non‑food crops
- Regulatory incentives for green pharmaceutical ingredients
- Expansion into emerging markets such as Asia‑Pacific and South America
- Top 10 Companies in the Methacrylate Adhesive for Structural Bonding of Thermoplastic Composites Market (2026): Market Leaders Driving Lightweight Innovation - June 16, 2026
- Top 10 Companies in the Flat Roof Adhesive Market (2026): Market Leaders Driving Global Roofing - June 16, 2026
- Top 10 Companies in the Galfan-Coated Steel Market (2026): Market Leaders Powering Global Industry - June 16, 2026